Roche touts early trial success of second obesity drug candidate
Roche’s incursion into obesity seems to be paying off based on the first readout since the drugmaker scooped up Carmot Therapeutics for $2.7 billion.
Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced last year.
Carmot Therapeutics Announces Completion of Acquisition by Roche
A week after one obesity biotech, Carmot Therapeutics, backed out of its IPO plans in favor of a $2.7 billion sale to Roche, another announced plans to go public on Nasdaq.
Roche joins race for obesity drugs with $2.7 billion Carmot deal
Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments Carmot will join the Roche Group as part of Roche™s Pharmaceuticals...
Carmot Therapeutics has filed to go public in a chilly environment for new listings, but the obesity biotech’s place in one of drug development’s hottest fields could buoy its chances of a successful IPO.
“ Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes (T1D) “ “ A second mechanistic clinical trial is...
CT-388 administered once-weekly resulted in clinically meaningful weight loss and insulin sensitivity over a 4 week treatment period in participants with overweight or obesity without type 2...